GLP1R and familial pancreatic carcinoma: For pancreatic cancer, the overall pooled analysis (Figure S3) demonstrated no significant association with GLP‐1 RA use (RR = 1.30, 95% CI: 0.86–1.97, p = 0.22, I2 = 0%).